Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Filed Feb 15, 2024 · 10-K · 46 days after period end · 0001178670-24-000008
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $439.72M | $335.04M | $258.54M | $163.56M |
| Net Income | -$137.87M | -$207.49M | -$258.46M | -$243.54M |
| EPS Diluted | — | — |
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
| — |
| -$2.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 15, 2024 · 46 d after period end
